L-carnitine as an add-on therapy for critically ill patients with liver disease in the ICU

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial tests adjunctive L-carnitine therapy in adults with acute or decompensated liver disease who are hospitalized in the ICU. Participants receive L-carnitine in addition to standard medical treatment to see if it improves outcomes. The study targets patients with conditions such as hepatic encephalopathy, variceal bleeding, and related organ dysfunction, reflecting the high risk profile of decompensated cirrhosis. The design is interventional, adding L-carnitine to usual care, in a Phase 4 setting. Safety and clinical outcomes will be monitored to determine potential benefits and risks.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age more than 18 years old
* male or female with confirmed liver disease admitted to intensive care unit, including:
* Acute-on-chronic liver failure (ACLF)
* Hepatic encephalopathy
* spontaneous bacterial peritonitis (SBP)
* variceal bleeding
* fulminant hepatitis
* Hepatorenal syndrome
* Ascites
* Etc

Exclusion Criteria:

* Age of less than 18 years old
* Pregnancy or Lactation
* patients have seizure
* patient on warfarin

Where it's running

• National liver institute
  Shibīn al Kawm, Egypt Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Coil-assisted small-diameter stent shunt reduction for refractory HE after TIPS

  A coil-assisted, small-diameter covered-stent technique is being tested to see if it can safely and effectively reduce shunt flow and lessen recurrent hepatic encephalopathy in people with a prior TIPS.

  Recruiting Air Force Military Medical University, China · Xi'an, Shaanxi · NCT07799948

• Fecal transplant plus standard therapy for refractory hepatic encephalopathy after TIPS

  This study tests whether adding fecal microbiota transplantation to usual medicines helps people with recurrent hepatic encephalopathy after TIPS implant.

  Recruiting Early Phase 1 Air Force Military Medical University, China · Xi'an · NCT07683936

• Apixaban plus carvedilol to prevent portal-hypertension complications in cirrhosis

  This will test whether adding apixaban to carvedilol can help prevent variceal bleeding, portal vein thrombosis, and other portal-hypertension complications in adults with Child-Pugh B cirrhosis.

  Recruiting Phase 4 Asian Institute Of Medical Sciences · Hyderābād, Sindh · NCT07521332

• Developing and testing the Liver Cirrhosis Cognitive Decline Scale (LiCCoS)

  This project will test a short questionnaire called LiCCoS to see if it can spot thinking and everyday mental problems in adults with liver cirrhosis.

  Recruiting University of Malaya · Ambāla, Haryana · NCT07418008

• Melatonin to improve sleep and thinking in people with cirrhosis

  This study will try one month of daily melatonin (compared with one month of thiamine) to see if it improves sleep and thinking in adults with cirrhosis and hepatic encephalopathy.

  Recruiting Weill Medical College of Cornell University · New York, New York · NCT07046429

• Examining the link between serum albumin levels and hepatic encephalopathy severity in chronic liver disease patients

  This study is trying to see if the level of a protein called serum albumin in the blood is related to how severe brain problems are in people with chronic liver disease.

  Recruiting Sohag University · Sohag · NCT06953921

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.